published meta-analysis   sensitivity analysis   studies

sarilumab high dose (400mg) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultssarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] 0.78[0.34; 1.80]sarilumab phase 2 high dose, 010%132seriousnot evaluable clinical improvementdetailed resultssarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] 2.09[1.00; 4.36]sarilumab phase 2 high dose, 010%132seriousnot evaluable death or ventilationdetailed resultssarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] 0.39[0.18; 0.82]sarilumab phase 2 high dose, 010%132seriousnot evaluable ventilationdetailed resultssarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] 0.27[0.10; 0.71]sarilumab phase 2 high dose, 010%132seriousnot evaluable off oxygenationdetailed resultssarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] 1.99[0.95; 4.15]sarilumab phase 2 high dose, 010%132seriousnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-27 17:06 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 646 - roots T: 290